The importance of clinical trials in unraveling the mysteries of multiple sclerosis

Henry McFarland

Research output: Contribution to journalArticle

Abstract

Despite a number of new therapies that are effective in reducing the inflammatory component of multiple sclerosis, the underlying cause of the disease remains uncertain. One of the most powerful tools available to an investigator to help in unraveling the underlying disease mechanisms in MS is the incorporation of careful imaging and laboratory studies into clinical trials. Regardless of the outcome of the trial with respect to modification of clinical disease, probing the biological effects of the treatment in relationship to the clinical outcome can provide important insights into the disease. Unfortunately, careful proof-of-principle laboratory studies are often not supported by the sponsors of clinical trials and mechanisms for rapid funding of supporting laboratory studies is difficult. Consequently important opportunities to better understand the disease are missed.

Original languageEnglish (US)
Pages (from-to)3-6
Number of pages4
JournalJournal of Neuroimmunology
Volume231
Issue number1-2
DOIs
StatePublished - Feb 2011
Externally publishedYes

Fingerprint

Multiple Sclerosis
Clinical Trials
Research Personnel
Therapeutics

Keywords

  • Clinical trials
  • Immunology
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

The importance of clinical trials in unraveling the mysteries of multiple sclerosis. / McFarland, Henry.

In: Journal of Neuroimmunology, Vol. 231, No. 1-2, 02.2011, p. 3-6.

Research output: Contribution to journalArticle

@article{5b82b0aa34874b419e7edc9343bbe15f,
title = "The importance of clinical trials in unraveling the mysteries of multiple sclerosis",
abstract = "Despite a number of new therapies that are effective in reducing the inflammatory component of multiple sclerosis, the underlying cause of the disease remains uncertain. One of the most powerful tools available to an investigator to help in unraveling the underlying disease mechanisms in MS is the incorporation of careful imaging and laboratory studies into clinical trials. Regardless of the outcome of the trial with respect to modification of clinical disease, probing the biological effects of the treatment in relationship to the clinical outcome can provide important insights into the disease. Unfortunately, careful proof-of-principle laboratory studies are often not supported by the sponsors of clinical trials and mechanisms for rapid funding of supporting laboratory studies is difficult. Consequently important opportunities to better understand the disease are missed.",
keywords = "Clinical trials, Immunology, Multiple sclerosis",
author = "Henry McFarland",
year = "2011",
month = "2",
doi = "10.1016/j.jneuroim.2010.12.010",
language = "English (US)",
volume = "231",
pages = "3--6",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - The importance of clinical trials in unraveling the mysteries of multiple sclerosis

AU - McFarland, Henry

PY - 2011/2

Y1 - 2011/2

N2 - Despite a number of new therapies that are effective in reducing the inflammatory component of multiple sclerosis, the underlying cause of the disease remains uncertain. One of the most powerful tools available to an investigator to help in unraveling the underlying disease mechanisms in MS is the incorporation of careful imaging and laboratory studies into clinical trials. Regardless of the outcome of the trial with respect to modification of clinical disease, probing the biological effects of the treatment in relationship to the clinical outcome can provide important insights into the disease. Unfortunately, careful proof-of-principle laboratory studies are often not supported by the sponsors of clinical trials and mechanisms for rapid funding of supporting laboratory studies is difficult. Consequently important opportunities to better understand the disease are missed.

AB - Despite a number of new therapies that are effective in reducing the inflammatory component of multiple sclerosis, the underlying cause of the disease remains uncertain. One of the most powerful tools available to an investigator to help in unraveling the underlying disease mechanisms in MS is the incorporation of careful imaging and laboratory studies into clinical trials. Regardless of the outcome of the trial with respect to modification of clinical disease, probing the biological effects of the treatment in relationship to the clinical outcome can provide important insights into the disease. Unfortunately, careful proof-of-principle laboratory studies are often not supported by the sponsors of clinical trials and mechanisms for rapid funding of supporting laboratory studies is difficult. Consequently important opportunities to better understand the disease are missed.

KW - Clinical trials

KW - Immunology

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=79952436010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952436010&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2010.12.010

DO - 10.1016/j.jneuroim.2010.12.010

M3 - Article

VL - 231

SP - 3

EP - 6

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -